Kushner Bradley, Allen Paul D, Crane Benjamin T
*University of Rochester School of Medicine †Department of Otolaryngology ‡Department of Neurobiology and Anatomy, University of Rochester Medical Center §Department of Bioengineering, University of Rochester, Rochester, New York, U.S.A.
Otol Neurotol. 2016 Feb;37(2):190-5. doi: 10.1097/MAO.0000000000000937.
To understand how aminoglycosides such as gentamicin are used in a tertiary care setting. To familiarize otologists with the demographics and risk factors associated with gentamicin use at major medical centers to allow the possibility of early intervention.
Retrospective review of existing clinical data.
University of Rochester Medical Center (URMC), including all associated hospitals (Strong Memorial Hospital, Highland Hospital, etc.).
All hospital inpatients who were prescribed intravenous gentamicin over a 4-year period starting in February 2011.
None.
Major patient populations receiving gentamicin and the associated diagnoses for which gentamicin was prescribed.
A total of 5,257 patients were found to have received gentamicin. Three major populations of patients were found to have received gentamicin: 1) more than half the gentamicin exposures were children and 42% were under 2 years. 2) 18% of the exposures were young adults age 18 to 34 and in this population 88% were woman with most of these hospitalizations pregnancy related. 3) Patients >55 were 19% of the exposures and most of these had serious infections. Disorders associated with patients receiving gentamicin included: perinatal complications (1,564); sepsis (1,399); acute/chronic renal disease (1,287); labor, delivery, or neonatal complications (1,250); diabetes (949); and UTI/pyelonephritis (775).
Gentamicin is still widely used, and the neonatal population and young adult women are at especially high risk for gentamicin-induced ototoxicity. Further data analysis should focus strategies to protect these populations by avoiding unnecessary exposures and by possible concurrent administration of protective medications such as metformin and aspirin.
了解庆大霉素等氨基糖苷类药物在三级医疗环境中的使用情况。使耳科医生熟悉主要医疗中心与庆大霉素使用相关的人口统计学和风险因素,以便进行早期干预。
对现有临床数据进行回顾性分析。
罗切斯特大学医学中心(URMC),包括所有附属医院(斯特朗纪念医院、高地医院等)。
2011年2月开始的4年期间内所有接受静脉注射庆大霉素的住院患者。
无。
接受庆大霉素治疗的主要患者群体以及使用庆大霉素的相关诊断。
共发现5257例患者接受了庆大霉素治疗。发现接受庆大霉素治疗的主要有三类患者群体:1)超过一半接受庆大霉素治疗的是儿童,42%的患者年龄在2岁以下。2)18%的治疗对象为18至34岁的年轻成年人,该群体中88%为女性,且大多数住院与妊娠相关。3)55岁以上的患者占治疗对象的19%,其中大多数患有严重感染。接受庆大霉素治疗的患者相关疾病包括:围产期并发症(1564例);败血症(1399例);急/慢性肾病(1287例);分娩、生产或新生儿并发症(1250例);糖尿病(949例);以及尿路感染/肾盂肾炎(775例)。
庆大霉素仍被广泛使用,新生儿群体和年轻成年女性尤其易发生庆大霉素所致耳毒性。进一步的数据分析应聚焦于通过避免不必要的接触以及可能同时使用如二甲双胍和阿司匹林等保护药物来保护这些群体的策略。